Compare PRGS & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRGS | SLBT |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | 20 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1995 | N/A |
| Metric | PRGS | SLBT |
|---|---|---|
| Price | $40.48 | $2.79 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $49.50 | N/A |
| AVG Volume (30 Days) | ★ 621.3K | 145.3K |
| Earning Date | 03-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.79 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $397,572,000.00 | N/A |
| Revenue This Year | $3.70 | N/A |
| Revenue Next Year | $1.08 | N/A |
| P/E Ratio | $39.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.82 | $2.54 |
| 52 Week High | $47.37 | $6.25 |
| Indicator | PRGS | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 35.84 |
| Support Level | $39.05 | N/A |
| Resistance Level | $40.85 | $4.91 |
| Average True Range (ATR) | 1.70 | 0.37 |
| MACD | -0.08 | -0.14 |
| Stochastic Oscillator | 51.18 | 7.91 |
Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.